Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01716715
Recruitment Status : Active, not recruiting
First Posted : October 30, 2012
Last Update Posted : September 28, 2018
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : October 1, 2018
Study Completion Date : No date given
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 June 26, 2019
July 17, 2019
2 October 2, 2019
October 23, 2019
3 January 31, 2020
February 10, 2020